Identification of key genes and pathways downstream of the β-catenin-TCF7L1 complex in pancreatic cancer cells using bioinformatics analysis

YI-HANG YUAN[1*], JIAN ZHOU[2*], YAN ZHANG[1*], MENG-DAN XU[1],
JING WU[1], WEI LI[1,3,4], MENG-YAO WU[1] and DAO-MING LI[1]

Departments of [1]Oncology and [2]General Surgery, The First Affiliated Hospital of Soochow University, Suzhou,
Jiangsu 215006; [3]PREMED Key Laboratory for Precision Medicine, Soochow University, Suzhou, Jiangsu 215021;
[4]Comprehensive Cancer Center, Suzhou Xiangcheng People's Hospital, Suzhou, Jiangsu 215000, P.R. China

Abstract. As a key component of the Wnt signaling pathway, the β-catenin-transcription factor 7 like 1 (TCF7L1) complex activates transcription and regulates downstream target genes that serve important roles in the pathology of pancreatic cancer. To identify associated key genes and pathways downstream of the β-catenin-TCF7L1 complex in pancreatic cancer cells, the current study used the gene expression profiles GSE57728 and GSE90926 downloaded from the Gene Expression Omnibus. GSE57728 is an array containing information regarding β-catenin knockdown and GSE90926 was developed by high throughput sequencing to provide information regarding TCF7L1 knockdown. Subsequently, differentially expressed genes (DEGs) were sorted separately and the shared 88 DEGs, including 37 upregulated and 51 downregulated genes, were screened. Clustering analysis of these DEGs was performed by heatmap analysis. Functional and pathway enrichment analyses were then performed using FunRich software and Database for Annotation, Visualization and Integrated Discovery, which revealed that the DEGs were predominantly enriched in terms associated with transport, transcription factor activity, and cytokine and chemokine mediated signaling pathway process. A DEG-associated protein-protein interaction (PPI) network, consisting of 58 nodes and 171 edges, was then constructed using Cytoscape software and the 15 genes with top node degrees were selected as the hub genes. Overall survival (OS) analysis of the 88 DEGs was performed and the relevant gene expression datasets were downloaded from The Cancer Genome Atlas. Consequently, three upregulated and seven downregulated genes were identified to be associated with prognosis. Furthermore, high expression levels of five downregulated genes, including CXCL5, CYP27C1, FUBP1, CDK14 and TRIM24, were associated with worse OS. In addition, CDK14 and TRIM24 were revealed as hub genes in the PPI network and both were confirmed to be involved in the Wnt/β-catenin pathway and phosphoinositide 3-kinase/Akt signaling pathway. Promoter analysis was also applied to the five downregulated DEGs associated with prognosis, which revealed that TCF7L1 may serve as a transcription factor of the DEGs. In conclusion, the genes and pathways identified in the current study may provide potential targets for the diagnosis and treatment of pancreatic cancer.

Introduction

Pancreatic cancer is a highly malignant tumor type of the digestive tract that is ranked as the fourth leading cause of cancer-associated mortality (1), with an estimated 55,440 new cases and an estimated 44,330 mortalities in the USA in 2018 according to statistics from Surveillance, Epidemiology, and End Results (2). Its aggressive biological properties, lack of early symptoms and rapid spread to surrounding organs lead are responsible for the high mortality rate (3). Furthermore, the treatment of pancreatic cancer is limited due to difficulties associated with surgical removal, and poor sensitivity to radiotherapy and chemotherapy (4-6). Therefore, identification of therapeutic targets is urgently required to improve patient outcome (7).

It has been reported that β-catenin, a versatile protein that mediates intercellular adhesion and gene expression, is abnormally expressed in pancreatic cancer (8). As the transcriptional cofactor of β-catenin, transcription factor 7 like 1 (TCF7L1), also termed transcription factor 3, is a member of the mammalian TCF/LEF family. Nuclear DNA-binding TCF/LEF proteins and β-catenin represent key components of the canonical branch of the Wnt signaling pathway, which serves a key role in pancreatic cancer carcinogenesis (9,10).

Once the Wnt pathway is activated, β-catenin accumulates in the cytoplasm and enters the nucleus, where it engages

Correspondence to: Dr Dao-Ming Li or Dr Meng-Yao Wu, Department of Oncology, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou, Jiangsu 215006, P.R. China
E-mail: licg2007@sina.com
E-mail: mywu@suda.edu.cn

*Contributed equally

DNA-bound TCF transcription factors and subsequently regulates the transcription of downstream target genes (11). It is understood that β-catenin and TCF7L1 are pivotal proteins in the Wnt/β-catenin pathway; therefore, the genes they regulate may be drug targets for pancreatic cancer (12).

In recent years, microarray and high throughput sequencing technologies have widely been used to explore the genetic characteristics of tumorigenesis, which may promote the development of diagnostic and treatment strategies (13). Bioinformatics research methods are required to handle large sample data; therefore, different databases have been established to provide convenience for research (14,15). In the present study, the gene expression profiles GSE57728, an array focused on β-catenin, and GSE90926, an array developed by high throughput sequencing regarding TCF7L1, were downloaded from the Gene Expression Omnibus (GEO) and analyzed to obtain the differentially expressed genes (DEGs) between pancreatic control groups and experimental groups. Clustering analysis, and functional and pathways enrichment analysis were performed to identify the associations and functions of the DEGs. In addition, a protein-protein interaction (PPI) network was constructed, and overall survival (OS) and promoter analyses was performed, to identify the associated key genes and pathways downstream of the β-catenin-TCF7L1 complex in pancreatic cancer cells.

Materials and methods

Collection and inclusion criteria of the studies. The GEO database (www.ncbi.nlm.nih.gov/geo/) was searched for the following keywords: 'pancreatic cancer' (study keyword), 'β-catenin' (study keyword), 'Homo sapiens' (organism) and 'Expression profiling by array or sequencing' (study type). This search revealed seven studies. The inclusion criteria for the studies were as follows: i) Samples were required to be in two groups, including the control group and the experimental group, ii) the sample count needed to be >10, iii) β-catenin or TCF7L1 in the experimental group should be overexpressed or inhibited, and iv) sufficient information had to be present to perform the analysis. Consequently, GSE57728 (16) was downloaded for analysis regarding β-catenin and GSE90926, which was contributed by Dr David Dawson (Dawson Laboratory, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA), was downloaded for analysis regarding TCF7L1.

Microarray data and validation. Two gene expression profiles (GSE57728 and GSE90926) were downloaded from the GEO database. The array data regarding β-catenin knockdown in GSE57728 included 16 samples, from this the present study selected two control samples with control small interfering RNA (siRNA) transfection and two experimental samples with β-catenin siRNA transfection for analysis. Similarly, the sequencing data regarding TCF7L1 knockdown in GSE90926 included 12 samples and the current study selected three control samples with control siRNA transfection and three experimental samples with TCF7L1 siRNA transfection for further analysis. Subsequently, a microarray assay regarding β-catenin knockdown was conducted to confirm the results from the microarray

data downloaded from the GEO database. This was performed based on previous studies in which relevant results regarding the Wnt pathway in pancreatic cancer were revealed, including the identification of FH535 as a small-molecule inhibitor of the Wnt/β-catenin signaling pathway (10,17). FH535, as a classic inhibitor of the β-catenin pathway which could repress pancreatic cancer cell growth and metastasis, played the same role as siRNA in the inhibition of the β-catenin pathway. Sample preparation and processing were performed as described in the GeneChip Expression Analysis Manual (Agilent Technologies, Inc., Santa Clara, CA, USA). Differentially expressed genes were screened using Agilent 44K human whole-genome oligonucleotide microarrays (Agilent Technologies, Inc.). After obtaining the two completed microarrays with different gene expressions, 10 shared genes were selected randomly and the gene expression levels of the control and experimental groups were compared to confirm that the data downloaded from the GEO database was reliable.

Data processing. R (version 3.3.3 for Windows; https://www.r-project.org/) is a software system used for data processing, computing and mapping based on the different R packages. The limma package was used to identify the DEGs by linear modeling of the genes. P<0.05 and a fold change >1.5 or <0.667 were set as the cut-off criteria. Subsequently, a heat map of DEGs was generated using R and P<0.05 was set as the cut-off criterion.

Functional and pathway enrichment analysis, and PPI network construction. Database for Annotation, Visualization and Integrated Discovery (DAVID) provides a comprehensive set of functional annotation tools for investigators to understand the biological meaning behind a large list of genes. FunRich is a stand-alone software tool used predominantly for functional enrichment and interaction network analysis of genes and proteins. The results of the analysis can be depicted graphically in the form of Venn, bar, column, pie and doughnut charts. In the present study, gene ontology (GO) enrichment analysis was performed for the identified DEGs using the FunRich (version 3.1.3 for Windows; http://www.funrich.org/) and DAVID databases (version 6.8; http://david.ncifcrf.gov/). P<0.05 was set as the cut-off criterion, however, for the sake of symmetry and sharp contrast, the P-value of several terms was >0.05. In every figure, eight columns were sorted using Funrich. Pathway enrichment analysis was performed for the identified DEGs using KOBAS (http://kobas.cbi.pku.edu.cn/), which is a web server for gene/protein functional annotation and functional gene set enrichment. In addition, the Kyoto Encyclopedia of Genes and Genomes (KEGG; https://www.kegg.jp/) database was used, which is an integrated database resource for biological interpretation of genome sequences and other high-throughput data (18). P<0.05 was set as the cut-off criterion. In addition, a PPI network of the DEGs was constructed using the STRING database (http://string-db.org/) and Cytoscape (version 3.7.1 for Windows; https://cytoscape.org/), which is a commonly used software to generate integrated models of biomolecular interaction networks. A combined score >0.15 was set as the cut-off criterion. To screen the hub genes, a node degree ≥8 was set as the cut-off criterion.

Figure 1. Microarray data and validation. Ten shared genes, including CGN, CNN3, DZIP1, EGR1, FBXL17, MDM2, SRXN1, HMOX1 and TMEM2, were selected to confirm the results from microarray data downloaded from the Gene Expression Omnibus database. Microarray analysis was performed to detect the expression of genes of samples transfected with 20 nM control siRNA or β-catenin siRNA in the original microarray data downloaded from GEO database. Microarray analysis was also performed to measure the expression of genes in samples treated with 20 μM FH535 in our own microarray data. The data are presented as the means ± standard deviation. *P<0.05 vs. respective control. siRNA, small interfering RNA; KD, knockdown.

Survival analysis of DEGs. Gene expression datasets were downloaded from The Cancer Genome Atlas (TCGA; https://tcga-data.nci.nih.gov/tcga) to analyze the prognosis of target DEGs. Data from a total of 178 patients with complete clinicopathological and RNASeq data were collected from the TCGA pancreatic cancer cohort. Clinical characteristics of the 178 patients are presented in Table I, including case ID, sex, year of birth, year of mortality, tumor stage, age at diagnosis measured in days, vital status and time from diagnosis to the last follow-up date or mortality. The patients were divided into two groups according to the expression of a particular gene, including a high expression group and a low expression group. The OS of patients with pancreatic cancer was analyzed using R software and the results were compared using Kaplan-Meier curves on which the P-value was presented. A log-rank test was conducted as the post hoc test.

Promoter analysis of DEGs. Ensemble (http://www.ensembl. org/index.html) is an online website that was used to perform promoter analysis of the DEGs. The eligible transcript of every DEG associated with prognosis was selected and then the 3,000 base pairs 5' upstream were selected as the promoter. Subsequently, the transcription factors (TFs) site analysis function of Genomatix (http://www.genomatix. de/solutions/genomatix-software-suite.html) was used to predict potential TF families and TF binding sites by analyzing the sequence of promoter obtained from Ensemble. Core similarity was set as 1 for an accurate prediction.

Results

Microarray data and validation. As demonstrated in the Fig. 1, ten genes that were shared between the original microarray

Table I. Clinical characteristics of 178 patients used for overall survival analysis.

Case ID	Sex	Year of birth	Year of mortality	Tumor stage	Age at diagnosis, days	Alive at last follow-up	Days from diagnosis to mortality	Days from diagnosis to last follow-up
1	Male	1929	2011	iib	30,092	No	292	-
2	Female	1942	-	iIb	26,179	No	375	1
3	Male	1970	-	iib	15,807	Yes	-	286
4	Male	1938	-	ib	27,362	No	498	449
5	Female	1953	-	iia	22,131	Yes	-	438
6	Male	1947	2012	iib	23,962	No	66	-
7	Male	1938	2013	iib	27,082	No	652	-
8	Female	1938	2014	iib	27,662	No	532	-
9	Male	1972	-	ia	14,729	Yes	-	1,037
10	Male	1932	-	iib	29,792	Yes	-	483
11	Male	1932	-	ib	29,631	Yes	-	7
12	Female	1938	-	iib	27,645	Yes	-	525
13	Female	1962	-	iib	18,202	No	913	648
14	Male	1962	-	iib	18,357	Yes	-	920
15	Male	1949	-	iib	23,152	Yes	-	666
16	Male	1926	2010	iia	29,633	No	1,101	-
17	Female	1957	2012	iib	20,051	No	511	-
18	Male	1936	2009	iib	26,085	No	1,059	-
19	Female	1946	-	ib	23,406	Yes	-	1,542
20	Male	1957	2013	iib	20,133	No	607	-
21	Male	1941	-	iib	24,760	Yes	-	2,285
22	Female	1940	-	iib	26,635	No	732	385
23	Male	1943	-	ib	24,621	Yes	-	998
24	Male	1933	-	iib	28,174	No	661	240
25	Female	1936	-	iib	24,025	No	2,036	1,953
26	Male	1937	-	iib	27,453	Yes	-	743
27	Male	1965	2012	iib	17,294	No	308	-
28	Female	1955	-	iib	20,741	Yes	-	392
29	Female	1930	2011	iib	29,585	No	153	-
30	Male	1964	-	iib	17,794	Yes	-	729
31	Female	1947	-	iv	24,291	Yes	-	420
32	Male	1925	2009	iia	30,571	No	480	-
33	Female	1932	-	iii	29,213	Yes	-	462
34	Female	1948	-	iib	23,672	Yes	-	635
35	Male	1964	-	iib	18,059	Yes	-	404
36	Male	1938	-	iia	27,684	No	267	110
37	Female	1936	-	iib	27,929	No	517	0
38	Female	1952	-	ib	21,732	Yes	-	1,103
39	Male	1941	-	iib	26,028	Yes	-	80
40	Female	1939	-	iia	27,152	Yes	-	467
41	Female	1946	-	iib	22,981	Yes	-	228
42	Female	1942	2013	iib	25,920	No	627	-
43	Male	1946	2012	iib	23,998	No	458	-
44	Female	1929	2011	iib	29,904	No	568	-
45	Female	1959	-	iib	19,064	No	593	20
46	Female	1928	-	ia	30,821	No	151	91
47	Male	1958	-	iib	19,904	Yes	-	767
48	Female	1946	-	iib	23,868	No	596	21
49	Male	1952	-	iib	21,676	Yes	-	522
50	Female	1947	2009	iib	22,990	No	110	-

Table I. Continued.

Case ID	Sex	Year of birth	Year of mortality	Tumor stage	Age at diagnosis, days	Alive at last follow-up	Days from diagnosis to mortality	Days from diagnosis to last follow-up
51	Female	1958	-	iia	19,839	No	299	28
52	Male	1936	-	iib	27,637	Yes	-	194
53	Female	1945	2010	iib	23,953	No	31	-
54	Male	1939	2013	iib	26,936	No	691	-
55	Female	1948	-	iib	22,376	Yes	-	2,016
56	Male	1939	-	ia	26,947	Yes	-	454
57	Male	1943	2011	iib	24,078	No	1,130	-
58	Female	1951	-	iia	22,090	Yes	-	840
59	Female	1965	-	iib	17,821	No	278	164
60	Female	1936	-	iib	28,434	No	160	11
61	Female	1945	2010	iib	23,580	No	603	-
62	Male	1926	2011	ia	31,319	No	244	-
63	Female	1968	-	i	14,599	Yes	-	2,741
64	Male	1954	-	iib	19,847	Yes	-	716
65	Female	1953	-	ib	22,126	Yes	-	9
66	Male	1978	-	iib	13,127	Yes	-	245
67	Male	1947	-	iia	24,007	Yes	-	586
68	Male	1944	2012	iia	24,731	No	634	-
69	Male	1959	-	iia	19,677	Yes	-	671
70	Male	1943	-	iv	25,849	Yes	-	603
71	Male	1937	-	iib	27,850	Yes	-	0
72	Female	1939	2013	ib	27,128	No	144	-
73	Male	1938	2010	iib	26,239	No	485	-
74	Female	1934	2008	iib	26,773	No	467	-
75	Male	1934	2010	iib	28,074	No	143	-
76	Male	1963	2013	iib	18,315	No	183	-
77	Male	1935	2009	ib	26,747	No	598	-
78	Male	1956	2012	iib	20,641	No	277	-
79	Male	1940	-	iib	26,503	Yes	-	657
80	Male	1937	-	iia	28,047	Yes	-	517
81	Female	1968	-	iib	16,255	No	470	247
82	Female	1933	-	iib	29,150	No	233	153
83	Male	1957	-	iib	20,071	No	592	360
84	Male	1945	-	iib	24,150	No	614	361
85	Female	1954	-	iib	21,491	Yes	-	660
86	Male	1947	2011	iib	23,713	No	216	-
87	Female	1944	-	iib	24,891	Yes	-	491
88	Male	1962	2011	iib	18,172	No	123	-
89	Female	1946	-	iv	24,043	No	394	347
90	Female	1947	2012	iib	23,431	No	460	-
91	Male	1936	-	iib	28,403	Yes	-	330
92	Female	1963	-	iib	18,607	No	366	202
93	Female	1956	-	iia	20,316	Yes	-	969
94	Female	1929	-	iib	30,684	Yes	-	225
95	Female	1940	-	iib	26,379	Yes	-	319
96	Female	1939	-	iib	27,295	No	393	127
97	Male	1945	-	ib	24,810	Yes	-	951
98	Female	1950	-	iib	23,218	No	313	155
99	Female	1950	-	iib	22,413	Yes	-	4
100	Female	1942	2011	iib	25,312	No	224	-

Table I. Continued.

Case ID	Sex	Year of birth	Year of mortality	Tumor stage	Age at diagnosis, days	Alive at last follow-up	Days from diagnosis to mortality	Days from diagnosis to last follow-up
101	Female	1948	2009	iib	21,611	No	741	-
102	Male	1955	2007	iib	19,287	No	61	-
103	Female	1955	2009	iib	19,718	No	486	-
104	Male	1945	-	iib	24,864	Yes	-	431
105	Male	1939	-	iib	25,809	Yes	-	289
106	Male	1950	-	iib	22,433	No	366	24
107	Male	1936	2013	iib	28,239	No	95	-
108	Female	1943	-	iib	25,412	No	179	4
109	Female	1926	2012	iib	31,393	No	481	-
110	Male	1946	-	iib	24,589	Yes	-	737
111	Female	1933	2011	iib	28,353	No	702	-
112	Female	1958	-	iib	20,366	Yes	-	33
113	Female	1950	-	iib	23,306	No	230	179
114	Male	1954	-	iib	21,024	No	518	8
115	Male	1945	2009	iia	23,703	No	117	-
116	Female	1922	2007	iib	31,074	No	155	-
117	Male	1950	-	iia	22,283	Yes	-	1,216
118	Female	1954	-	iv	21,501	No	545	5
119	Male	1931	2012	iib	29,674	No	120	-
120	Male	1957	-	iia	20,607	Yes	-	498
121	Female	1935	2012	iib	27,957	No	695	-
122	Female	1956	-	iib	20,858	Yes	-	395
123	Female	-	-	iia	17,628	Yes	-	584
124	Female	1949	2013	iib	23,622	No	239	-
125	Male	1934	-	iia	28,317	Yes	-	482
126	Male	1946	-	iia	23,760	Yes	-	314
127	Male	1946	2010	iib	23,443	No	12	-
128	Male	1937	2009	iv	26,216	No	619	-
129	Male	1930	2010	iib	29,319	No	123	-
130	Female	1946	-	ia	24,174	Yes	-	1,021
131	Female	1924	-	iib	32,475	No	421	233
132	Male	1944	-	ib	23,791	Yes	-	1,854
133	Male	1952	2009	iib	20,984	No	334	-
134	Male	1950	-	iia	22,425	Yes	-	1,287
135	Female	1951	-	iib	22,329	Yes	-	289
136	Female	1949	-	ib	23,685	Yes	-	95
137	Male	1935	-	iib	28,454	No	308	0
138	Male	1946	-	iib	24,576	Yes	-	338
139	Male	1952	-	Not reported	21,175	Yes	-	1,794
140	Female	1956	2012	ib	20,760	No	219	-
141	Male	1965	-	iib	16,766	Yes	-	1,323
142	Male	1970	-	iib	15,869	Yes	-	440
143	Female	1932	-	iib	28,554	Yes	-	1,257
144	Female	1943	-	iib	25,214	No	378	16
145	Male	1939	-	iib	26,573	Yes	-	969
146	Male	1964	-	iia	17,649	No	353	166
147	Female	1955	-	iib	21,484	Yes	-	463
148	Female	1963	2011	iib	16,126	No	1,502	-
149	Male	1941	-	iib	26,188	Yes	-	484
150	Male	1955	2012	iib	20,618	No	684	-

Table I. Continued.

Case ID	Sex	Year of birth	Year of mortality	Tumor stage	Age at diagnosis, days	Alive at last follow-up	Days from diagnosis to mortality	Days from diagnosis to last follow-up
151	Male	1937	2012	iia	27,600	No	293	-
152	Male	1942	-	iia	25,768	Yes	-	252
153	Female	1946	-	ib	22,799	Yes	-	2,084
154	Female	1940	-	iia	26,311	Yes	-	232
155	Male	1948	-	iib	23,801	Yes	-	287
156	Male	1942	-	iii	25,227	Yes	-	706
157	Male	1967	2009	iib	15,188	No	666	-
158	Female	1938	-	Not reported	26,859	Yes	-	388
159	Male	1947	2007	iib	22,148	No	145	-
160	Male	1939	2013	iib	26,745	No	430	-
161	Male	1954	-	Not reported	20,451	Yes	-	1,942
162	Male	1954	-	iib	21,792	Yes	-	350
163	Female	1928	2002	iii	26,881	No	541	-
164	Male	1962	2012	iia	18,475	No	128	-
165	Female	1942	2011	iia	24,117	No	1,332	-
166	Female	1950	2013	iib	22,400	No	738	-
167	Female	1932	-	iib	29,585	No	466	36
168	Male	1937	-	iib	28,013	Yes	-	8
169	Female	1949	-	iia	23,624	Yes	-	379
170	Male	1954	-	iib	21,277	Yes	-	416
171	Female	1962	-	iib	18,129	Yes	-	1,116
172	Male	1940	-	ib	26,167	No	236	0
173	Female	1959	-	ib	19,707	Yes	-	720
174	Male	1958	-	iib	19,315	Yes	-	1,383
175	Male	1939	-	iia	26,943	Yes	-	676
176	Male	1941	-	iib	26,129	No	365	329
177	Male	1937	2013	iia	26,234	No	2,182	-
178	Male	1940	-	iib	26,322	Yes	-	978

Tumor stage was determined according to the 7th Edition of the American Joint Committee on Cancer Staging Manual (61).

data downloaded from the GEO database and our own microarray data regarding β-catenin knockdown, including CGN, CNN3, DZIP1, EGR1, FBXL17, MDM2, SRXN1, HMOX1 and TMEM2, were selected to confirm the results from microarray data downloaded from the GEO database. The results obtained for samples with β-catenin siRNA transfection and samples treated with FH535 exhibited consistent trends, with the exception of the results for IL32, HMOX1 and TMEM2.

Identification of DEGs and clustering analysis. A total of 1,784 DEGs, including, 812 upregulated and 972 downregulated genes, were identified from GSE90926 regarding TCF7L1 knockdown. A total of 2,013 DEGs, including 1,000 upregulated and 1,013 downregulated genes, were identified from GSE57728 regarding β-catenin knockdown. Among these DEGs, 88 DEGs were screened out as shared by the two datasets. The upregulated and downregulated DEGs were considered separately when selecting the shared genes. As a result, 37 upregulated and 51 downregulated DEGs were

identified (Fig. 2A and B; Table II). The respective heatmaps of the 88 DEGs were generated by R software (Fig. 2C and D).

Functional and pathway enrichment analysis, and PPI network construction. To investigate the function of the DEGs, functional enrichment analysis was performed. Analysis using FunRich software indicated that the DEGs were predominantly enriched in the following biological process terms: Transport, amino acid transport, transcription, cytokine and chemokine mediated signaling pathway, and carbohydrate metabolism (Fig. 3A and B). In addition, the DEGs were predominantly enriched in following cell component terms: Cytoplasmic cyclin-dependent protein kinase holoenzyme complex, interacted disc, M band and DNA-directed RNA polymerase III complex (Fig. 3C and D). Furthermore, for molecular function, the DEGs were enriched in the following terms: Transcription factor activity, DNA-directed RNA polymerase activity, amino acid transporter activity, transcription and lipid binding (Fig. 3E and F).

Table II. Identification of differentially expressed genes.

Regulation	Genes name
Upregulated	MMP19, OBSL1, KIT, PDSS1, SYT5, KLHL9, KCNT2, PPL, KRT7, FBXL17, SH2D3C, MR1, C10orf54, IL32, FLG-AS1, SLC9A1, TDRP, GPSM3, CGN, FKBP1A-SDCBP2, CASK, WDFY2, SLC35F3, SLC7A2, EBF4, KCTD18, SLITRK6, IRF9, STC1, CLIC3, SLC6A6, CYP1A1, GATSL2, NOTUM, TP53INP1, CACNA2D1, SPOCK3.
Downregulated	POLR3G, MNS1, ZMAT1, CXCL5, PMP2, DEPDC1, TRIM24, SRXN1, CYP27C1, GPR180, OSBPL6, DNAI1, DCLRE1A, POLR3B, PCDHGA1, CLUL1, C3orf14, SMC5, EGR1, PDK4, RPS6KA5, CLEC2B, SFXN2, HAGLR, PDCD4, RHEBL1, RRBP1, NFIB, DHX34, UBE2Q2L, EOMES, MDM2, FUBP1, DNAH1, DSTYK, ESX1, TET1, ODF2L, NSD1, SSH2, PTX3, LINC00173, MYCL, TMEM2, GRB14, TNFRSF19, CDK14, FRA10AC1, SOX17, PXYLP1, ZNF618.

Figure 2. Identification of DEGS. (A and B) Identification of DEGs in the expression profiling TCF7L1 KD dataset GSE90926 and the β-catenin KD dataset GSE57728. A total of 88 shared DEGs were identified, including 37 upregulated and 51 downregulated DEGs. (C and D) Heatmaps of the shared 88 DEGs of the two GSE datasets were generated by R software. Red indicates upregulation and green indicates downregulation. DEG, differentially expressed gene; KD, knockdown; TCF7L1, transcription factor 7 like 1; siRNA, small interfering RNA; Rep, replication.

Table III. GO analysis of differentially expressed genes in pancreatic cancer.

Category	Term	Count	%	P-value[a]
GOTERM_BP_DIRECT	GO:1904761~negative regulation of myofibroblast differentiation	2	2.272727273	0.009268837
GOTERM_BP_DIRECT	GO:0019827~stem cell population maintenance	3	3.409090909	0.02259656
GOTERM_MF_DIRECT	GO:0002039~p53 binding	3	3.409090909	0.033191281
GOTERM_BP_DIRECT	GO:0071236~cellular response to antibiotic	2	2.272727273	0.036569485
GOTERM_BP_DIRECT	GO:0001706~endoderm formation	2	2.272727273	0.054355943
GOTERM_BP_DIRECT	GO:0003351~epithelial cilium movement	2	2.272727273	0.058751666
GOTERM_BP_DIRECT	GO:0071391~cellular response to estrogen stimulus	2	2.272727273	0.058751666
GOTERM_MF_DIRECT	GO:0000977~RNA polymerase II regulatory region sequence-specific DNA binding	4	4.545454545	0.059249025
GOTERM_BP_DIRECT	GO:0070498~interleukin-1-mediated signaling pathway	2	2.272727273	0.063127217
GOTERM_BP_DIRECT	GO:0006885~regulation of pH	2	2.272727273	0.071818168
GOTERM_BP_DIRECT	GO:0090280~positive regulation of calcium ion import	2	2.272727273	0.071818168
GOTERM_BP_DIRECT	GO:0071456~cellular response to hypoxia	3	3.409090909	0.07344514
GOTERM_MF_DIRECT	GO:0001056~RNA polymerase III activity	2	2.272727273	0.074087687
GOTERM_CC_DIRECT	GO:0005666~DNA-directed RNA polymerase III complex	2	2.272727273	0.079265755
GOTERM_BP_DIRECT	GO:0045089~positive regulation of innate immune response	2	2.272727273	0.08042952
GOTERM_BP_DIRECT	GO:0002690~positive regulation of leukocyte chemotaxis	2	2.272727273	0.08042952
GOTERM_BP_DIRECT	GO:0045892~negative regulation of transcription, DNA-templated	6	6.818181818	0.082369804
GOTERM_BP_DIRECT	GO:0045944~positive regulation of transcription from RNA polymerase II promoter	9	10.22727273	0.084587325
GOTERM_CC_DIRECT	GO:0036126~sperm flagellum	2	2.272727273	0.087239628
GOTERM_BP_DIRECT	GO:0006366~transcription from RNA polymerase II promoter	6	6.818181818	0.090139483

[a]P<0.05 was set as the cut-off criterion. Count, the number of enriched genes in each term; GO, gene ontology; BP, biological processes; CC, cell component; MF, molecular function.

Using the DAVID database, GO analysis identified that the DEGs were enriched in the following terms: Negative regulation of myofibroblast differentiation, stem cell population maintenance and cellular response to antibiotic (Fig. 3G; Table III).

KEGG pathway analysis using KOBAS revealed that the DEGs were significantly enriched in the following terms: RNA polymerase, Wnt signaling pathway and cytokine-cytokine receptor interaction (Fig. 3H; Table IV).

The PPI network of DEGs consisted of 58 nodes and 171 edges, including 24 upregulated genes and 34 downregulated genes (Fig. 3I). As aforementioned, the shared 88 DEGs sorted from the two GSE datasets included 37 upregulated and 51 downregulated genes; however, all shared DEGs were not included in the PPI network as certain genes that were isolated at the edge were removed. Therefore, as presented in Fig. 3I, 58 shared DEGs were included in the PPI network, in which the red nodes represent the upregulated genes and the green nodes represent the downregulated genes. Furthermore, the most significant hub genes were selected as those with the highest numbers of edges. A total of 15 genes were selected as hub genes, including WDFY2, KIT, EGR1, NSD1, DSTYK, CDK14, MDM2, RPS6KA5, CYP1A1, POLR3B, SMC5, DNAI1, SSH2, TRIM24 and CASK.

OS analysis. OS analysis was performed using R software to investigate the prognostic value of the 88 DEGs and the results were presented as Kaplan-Meier curves. Among the 37 upregulated DEGs, CASK, IL32, and KRT7 were significantly associated with prognosis. In addition, among the 51 downregulated DEGs, the expression levels of CDK14, CXCL5, CYP27C1, DNAI1, FUBP1, TRIM24 and ZMAT1 were identified to be significantly associated with prognosis (Fig. 4). Furthermore, among the downregulated DEGs, high expression levels of CXCL5, CYP27C1, FUBP1, CDK14 and TRIM24 were associated with significantly worse overall survival (Fig. 4), which suggests inhibition of the β-catenin-TCF7L1 complex may result in the downregulation of these five potential oncogenic genes. Notably, CDK14 and TRIM24 were identified as hub genes in the PPI network, which indicates these genes may be the key downstream regulators of the β-catenin-TCF7L1 complex.

Promoter analysis of DEGs. Promoter analysis of DEGs performed using the Ensemble and Genomatix databases revealed that the predicted TFs of the five DEGs associated with poor OS, including CXCL5, CYP27C1, FUBP1, CDK14 and TRIM24, covered different TF families. Only TFs

Figure 3. Functional and pathway enrichment analysis, and PPI network construction. Functional enrichment analysis of the identified DEGs was performed by FunRich with the following three parts: (A and B) Biological processes, (C and D) cell component and (E and F) molecular function. (G) GO analysis of identified DEGs using Database for Annotation, Visualization and Integrated Discovery. (H) Kyoto Encyclopedia of Genes and Genomes pathway analysis of identified DEGs using KOBAS. (I) PPI network of the DEGs consisting of 58 nodes and 171 edges, including 24 upregulated genes (red) and 34 downregulated genes (green). PPI, protein-protein interaction; DEG, differentially expressed gene; GO, gene ontology.

Table IV. Kyoto Encyclopedia of Genes and Genomes signaling pathway enrichment analysis of differentially expressed genes in pancreatic cancer.

Pathway ID	Term	Count	P-value[a]
hsa03020	RNA polymerase	2	0.002583461
hsa05219	Bladder cancer	2	0.004105174
hsa04261	Adrenergic signaling in cardiomyocytes	3	0.004711319
hsa04623	Cytosolic DNA-sensing pathway	2	0.009436485
hsa05169	Epstein-Barr virus infection	3	0.010969532
hsa05205	Proteoglycans in cancer	3	0.011112587
hsa04260	Cardiac muscle contraction	2	0.013627503
hsa04060	Cytokine-cytokine receptor interaction	3	0.021708158
hsa00240	Pyrimidine metabolism	2	0.023537332
hsa04668	TNF signaling pathway	2	0.025617518
hsa04919	Thyroid hormone signaling pathway	2	0.029094794
hsa05206	MicroRNAs in cancer	3	0.029496436
hsa04120	Ubiquitin mediated proteolysis	2	0.038049532
hsa04530	Tight junction	2	0.039046349
hsa04310	Wnt signaling pathway	2	0.041069627
hsa00900	Terpenoid backbone biosynthesis	1	0.049591361

[a]$P < 0.05$ was set as the cut-off criterion. Count, the number of enriched genes in each term.

associated with TCF7L1 were selected to obtain a precise result. As presented in the Fig. 5, TCF7L1 was identified as a TF of four of the DEGs but not CXCL5. This result suggests that TCF7L1 may not be a TF of CXCL5, however, certain unavoidable errors of the prediction may have occurred. Furthermore, the locations of predicted TF sites of each promoter are demonstrated distinctly in Fig. 5. Two DEGs, including CDK14 and FUBP1, exhibited only one TF site, whereas, TRIM24 and CYP27C1 possessed two different sites. In addition, the locations of the two TF sites of TRIM24 were separated by <5 base pairs (Fig. 5).

Discussion

Pancreatic cancer is a highly lethal type of tumor of the digestive tract as its mortality rate is closely associated with the incidence rate (19). The majority of patients with pancreatic cancer exhibit no clinical signs until the disease reaches an advanced stage (20). Despite rapid developments in treatment strategies, effective early detective tests and drug targets for pancreatic cancer remain limited (21). Therefore, further understanding of the mechanisms underlying pancreatic cancer carcinogenesis is essential to improve prognosis and reduce the mortality rate. With developments in microarray technology, it can be useful to determine the general genetic alterations associated with disease progression, which may provide beneficial insight into the diagnosis, treatment and prognosis of the disease (22).

The present study selected two datasets of pancreatic cancer in which β-catenin and TCF7L1 knockdown had been performed separately to identify DEGs. A total of 88 shared DEGs were screened out consisting of 37 upregulated and 51 downregulated DEGs. According to functional and pathway

enrichment analysis, the shared DEGs were predominantly involved in transport, transcription, and the cytokine and chemokine mediated signaling pathway process. Furthermore, a PPI network was constructed and 15 genes were selected as hub genes, including WDFY2, KIT, EGR1, NSD1, DSTYK, CDK14, MDM2, RPS6KA5, CYP1A1, POLR3B, SMC5, DNAI1, SSH2, TRIM24 and CASK. According to OS analysis, high expression levels of CXCL5, CYP27C1, FUBP1, CDK14 and TRIM24, which were downregulated by inhibition of the β-catenin-TCF7L1 complex, were associated with worse prognosis. Notably, both CDK14 and TRIM24 were identified as hub genes in the PPI network and were negatively associated with OS, which suggests these two genes may serve key roles downstream of β-catenin-TCF7L1 complex.

CDK14, a member of the cyclin-dependent kinases, is a cdc2-associated serine/threonine protein kinase, which serves a vital role in normal cell cycle progression (23). It has been reported that CDK14 may interact with cyclin D3 and human cyclin Y to regulate cell cycle and cell proliferation (24,25). Furthermore, certain reports have suggested that CDK14 also regulates a number of pathways, including the Wnt/β-catenin signaling pathway and phosphoinositide 3-kinase (PI3K)/Akt signaling pathway, and cellular mechanisms to act as an oncogene (26,27). It is understood that the Wnt/β-catenin signaling pathway is a conserved signaling pathway associated with cell proliferation, migration, apoptosis, differentiation and normal stem cell self-renewal (28). In the absence of Wnt signaling, the mitosis-specific CDK14-Cyclin Y kinase complex phosphorylates Ser-1490 of LRP5/6, which are co-receptors for Wnt ligands at the G2/M stage, thereby triggering the receptor for Wnt-induced phosphorylation (29,30). Furthermore, a previous study has identified that CDK14 is highly expressed in pancreatic cancer, which promotes the proliferation,

Figure 4. Overall survival analysis. Ten DEGs of the 88 DEGs were selected for overall survival analysis, including the upregulated genes CASK, IL32 and KRT7, and the downregulated genes CDK14, CXCL5, CYP27C1, DNAI1, FUBP1, TRIM24 and ZMAT1. Overall survival analysis was performed using R software. DEG, differentially expressed gene.

migration and invasion of cancer cells (31). In addition, this high expression has been observed in a number of other types of malignant tumor, including hepatocellular carcinoma, gastric cancer and breast cancer (26,32,33). By contrast, knockout or inhibition of CDK14 has been demonstrated to exhibit a benefit on the prognosis of cancer types, including ovarian cancer and breast cancer (32,34). Furthermore, the PI3K/Akt signaling pathway also serves a vital role in cell

proliferation, migration, apoptosis and differentiation, and dysregulation of this pathway is common in pancreatic cancer. A previous study demonstrated that knockdown of CDK14 inhibited the proliferation and invasion of pancreatic cancer cells, in addition to the epithelial-to-mesenchymal transition, by suppressing the PI3K/Akt signaling pathway (31).

TRIM24, also termed transcription intermediary factor 1-α, is a member of the transcription intermediary factor family and

Figure 5. Promoter analysis of DEGs. Five DEGs including, CDK14, CYP27C1, FUBP1, CXCL5 and TRIM24 were analyzed using the Ensemble and Genomatix database to predict their interaction with the transcription factor TCF7L1, which belongs to the LEF-TCF family. The locations of the predicted TCF7L1 sites of each promoter are demonstrated with blue vertical line and numbers. +1 indicates the translation start site. Grey boxes represent exons. DEG, differentially expressed gene; TCF7L1, transcription factor 7 like 1.

has been confirmed to serve a key role in tumor development and progression (35,36). Furthermore, previous studies have demonstrated that TRIM24 is upregulated in several types of cancer and involved in numerous pathways. For example, certain studies have identified that TRIM24 is overexpressed, and promotes cancer cell growth and invasion in bladder cancer and cervical cancer, possibly via the nuclear factor-κB and PI3K/Akt signaling pathways (36,37). Similarly, it has been

reported that TRIM24 can accelerate cell growth and facilitate gastric cancer progression by activation of the Akt pathway (37) and the Wnt/β-catenin signaling pathway (38). Notably, in contrast to the aforementioned studies that suggest TRIM24 is an important oncogene in tumor development, TRIM24 has been identified to suppress the progression of murine hepato-cellular carcinoma (39). Therefore, the contradictory role or TRIM24 requires further investigation.

In addition to CDK14 and TRIM24, three other genes downstream of β-catenin-TCF7L1 were revealed to be negatively associated with prognosis including, CXCL5, CYP27C1 and FUBP1. CXCL5, CYP27C1 and FUBP1 were not identified as hub genes in the PPI network; however, these genes may also be target genes that affect OS and respond to the β-catenin-TCF7L1 complex.

FUBP1 encodes far upstream element-binding protein 1; a single stranded DNA-binding protein containing three domains that contribute to c-myc transcriptional regulation by binding to the far upstream element (40,41). As a member of the myc oncoprotein family, c-myc has been confirmed to be associated with oncogenesis (42,43). Therefore, it is not surprising that FUBP1 has also been revealed to be expressed in many types of malignant tissue and promote tumor proliferation and migration, and led to poor prognosis (44,45), which is consistent with the previous study. In addition, FUBP1 has been identified to function as an oncogene by regulating c-myc transcription in tumor progression (46). By contrast, the role of FUBP1 tumorigenesis may be c-myc independent, as a previous report demonstrated that knockdown of FUBP1 had no effect on the level of c-myc in hepatocellular carcinoma (44). In summary, FUBP1 may serve as a potential drug target due to its significant role in tumorigenesis. A recent study revealed that camptothecin and its analog SN-38, the active metabolite of irinotecan, may serve as a novel therapy for hepatocellular carcinoma by targeting FUBP1 (47). In addition, a previous study suggested that miR-16 may suppress FUBP1, both of which were associated with the trastuzumab response in ErbB-2-positive primary breast cancer (48).

CXCL5 is a member of the CXC subfamily of chemokines, which are produced locally in tissues. These chemokines function by interacting with specific G protein-coupled receptors, which are mainly expressed on leukocytes (49). It is well understood that chemokines serve a key role in infection and inflammation. Similarly, a number of reports have suggested that CXCL5 may contribute to pathogen- and auto-immune-induced inflammatory reactions, and angiogenesis by driving neutrophil recruitment (50,51). Furthermore, CXCL5 has also been confirmed to participate in cancer progression. Previous studies have demonstrated that overexpression of CXCL5 mediates neutrophil infiltration, and promotes cell proliferation and invasion in different types of tumor, including hepatocellular carcinoma and colorectal cancer, which suggests a poor prognosis (52,53). Knockdown of CXCL5 has been revealed to inhibit the proliferation and migration of human bladder cancer T24 cells (54). Furthermore, CXCL5 is associated with the PI3K/Akt/glycogen synthase kinase-3β/Snail signaling pathway (55,56) and epidermal growth factor (EGF)-EGF receptor signaling pathway (57), which have been demonstrated to serve significant roles in tumorigenesis.

CYP27C1 belongs to the cytochrome P450 superfamily of enzymes, which is understood to catalyze a number of reactions associated with drug metabolism (58). However, the number of studies regarding CYP27C1 is very limited. Certain studies have revealed that CYP27C1 can convert vitamin A1 into A2, which could be a switch for visual sensitivity (59,60). However, the other functions of this gene require further investigation.

In conclusion, the genes identified in the current study may serve as potential targets in pancreatic cancer. Furthermore, the associated functions and pathways may also provide information that can assist with the diagnosis and treatment of patients with pancreatic cancer. However, it is undeniable that there is a limitation of the present study due to the lack of experimental validation. In the future, the results predicted by bioinformatics analysis may be verified by advanced research and technology to provide benefits for the clinical outcome of patients with pancreatic cancer. In summary, the genes identified in the present study may provide potential targets for the diagnosis and treatment of pancreatic cancer, and they need to be validated prior to clinical use.

Availability of data and materials

All data generated or analyzed during the present study are included in this published article.

Authors' contributions

YHY, JZ and YZ participated in the design of this study and performed the statistical analysis. JZ collected important background information and contributed to the data acquisition. YZ carried out the study and contributed to figure preparation. YHY drafted the manuscript. MDX, JW and WL contributed to data acquisition, data analysis and statistical analysis. MYW and DML made great contributions to the original conception of the study and perfomed part of the data analysis. In addition, MYW and DML also performed manuscript review and critically revised the manuscript for important intellectual content. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin 65: 5-29, 2015.
2. Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin 68: 7-30, 2018.
3. Oberstein PE and Olive KP: Pancreatic cancer: Why is it so hard to treat? Therap Adv Gastroenterol 6: 321-337, 2013.
4. Long J, Luo GP, Xiao ZW, Liu ZQ, Guo M, Liu L, Liu C, Xu J, Gao YT, Zheng Y, *et al*: Cancer statistics: Current diagnosis and treatment of pancreatic cancer in Shanghai, China. Cancer Lett 346: 273-277, 2014.

5. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD and Hingorani SR: Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21: 418-429, 2012.
6. Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK and Hruban RH: Recent progress in pancreatic cancer. CA Cancer J Clin 63: 318-348, 2013.
7. Stathis A and Moore MJ: Advanced pancreatic carcinoma: Current treatment and future challenges. Nat Rev Clin Oncol 7: 163-172, 2010.
8. Wang Z, Ma Q, Li P, Sha H, Li X and Xu J: Aberrant expression of CXCR4 and β-catenin in pancreatic cancer. Anticancer Res 33: 4103-4110, 2013.
9. Hrckulak D, Kolar M, Strnad H and Korinek V: TCF/LEF transcription factors: An update from the internet resources. Cancers 8: pii: E70, 2016.
10. Liu L, Zhi Q, Shen M, Gong FR, Zhou BP, Lian L, Shen B, Chen K, Duan W, Wu MY, et al: FH535, a β-catenin pathway inhibitor, represses pancreatic cancer xenograft growth and angiogenesis. Oncotarget 7: 47145-47162, 2016.
11. Behrens J, von Kries JP, Kühl M, Bruhn L, Wedlich D, Grosschedl R and Birchmeier W: Functional interaction of beta-catenin with the transcription factor LEF-1. Nature 382: 638-642, 1996.
12. Shang S, Hua F and Hu ZW: The regulation of β-catenin activity and function in cancer: Therapeutic opportunities. Oncotarget 8: 33972-33989, 2017.
13. Duarte JG and Blackburn JM: Advances in the development of human protein microarrays. Expert Rev Proteomics 14: 627-641, 2017.
14. Sato Y, Miya M, Fukunaga T, Sado T and Iwasaki W: MitoFish and MiFish pipeline: A mitochondrial genome database of fish with an analysis pipeline for environmental DNA metabarcoding. Mol Biol Evol 35: 1553-1555, 2018.
15. Győrffy B, Pongor L, Bottai G, Li X, Budczies J, Szabó A, Hatzis C, Pusztai L and Santarpia L: An integrative bioinformatics approach reveals coding and non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes. Br J Cancer 118: 1107-1114, 2018.
16. Arensman MD, Telesca D, Lay AR, Kershaw KM, Wu N, Donahue TR and Dawson DW: The CREB-binding protein inhibitor ICG-001 suppresses pancreatic cancer growth. Mol Cancer Ther 13: 2303-2314, 2014.
17. Wu MY, Liang RR, Chen K, Shen M, Tian YL, Li DM, Duan WM, Gui Q, Gong FR, Lian L, et al: FH535 inhibited metastasis and growth of pancreatic cancer cells. Onco Targets Ther 8: 1651-1670, 2015.
18. Kanehisa M, Sato Y, Kawashima M, Furumichi M and Tanabe M: KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res 44 (D1): D457-D462, 2016.
19. Kamisawa T, Wood LD, Itoi T and Takaori K: Pancreatic cancer. Lancet 388: 73-85, 2016.
20. Ilic M and Ilic I: Epidemiology of pancreatic cancer. World J Gastroenterol 22: 9694-9705, 2016.
21. Mohammed S, Van Buren G II and Fisher WE: Pancreatic cancer: Advances in treatment. World J Gastroenterol 20: 9354-9360, 2014.
22. López-Casas PP and López-Fernández LA: Gene-expression profiling in pancreatic cancer. Expert Rev Mol Diagn 10: 591-601, 2010.
23. Duan C, Liu Y, Lu L, Cai R, Xue H, Mao X, Chen C, Qian R, Zhang D and Shen A: CDK14 contributes to reactive gliosis via interaction with cyclin Y in rat model of spinal cord injury. J Mol Neurosci 57: 571-579, 2015.
24. Hamilton T and Schifrin BS: Delayed cesarean section in preeclampsia with placental abruption and fetal distress. J Perinatol 11: 182-185, 1991.
25. Li S, Song W, Jiang M, Zeng L, Zhu X and Chen J: Phosphorylation of cyclin Y by CDK14 induces its ubiquitination and degradation. FEBS Lett 588: 1989-1996, 2014.
26. Yang W, Zhu J, Huang H, Yang Q, Cai J, Wang Q, Zhu J, Shao M, Xiao J, Cao J, et al: PFTK1 promotes gastric cancer progression by regulating proliferation, migration and invasion. PLoS One 10: e0140451, 2015.
27. Wang B, Zou A, Ma L, Chen X, Wang L, Zeng X and Tan T: miR-455 inhibits breast cancer cell proliferation through targeting CDK14. Eur J Pharmacol 807: 138-143, 2017.
28. Prakash N and Wurst W: A Wnt signal regulates stem cell fate and differentiation in vivo. Neurodegener Dis 4: 333-338, 2007.
29. Davidson G and Niehrs C: Emerging links between CDK cell cycle regulators and Wnt signaling. Trends Cell Biol 20: 453-460, 2010.
30. Wang X, Jia Y, Fei C, Song X and Li L: Activation/proliferation-associated protein 2 (Caprin-2) positively regulates CDK14/Cyclin Y-mediated lipoprotein receptor-related protein 5 and 6 (LRP5/6) constitutive phosphorylation. J Biol Chem 291: 26427-26434, 2016.
31. Zheng L, Zhou Z and He Z: Knockdown of PFTK1 inhibits tumor cell proliferation, invasion and epithelial-to-mesenchymal transition in pancreatic cancer. Int J Clin Exp Pathol 8: 14005-14012, 2015.
32. Gu X, Wang Y, Wang H, Ni Q, Zhang C, Zhu J, Huang W, Xu P, Mao G and Yang S: Upregulated PFTK1 promotes tumor cell proliferation, migration, and invasion in breast cancer. Med Oncol 32: 195, 2015.
33. Du B, Zhang P, Tan Z and Xu J: MiR-1202 suppresses hepatocellular carcinoma cells migration and invasion by targeting cyclin dependent kinase 14. Biomed Pharmacother 96: 1246-1252, 2017.
34. Zhang W, Liu R, Tang C, Xi Q, Lu S, Chen W, Zhu L, Cheng J, Chen Y, Wang W, et al: PFTK1 regulates cell proliferation, migration and invasion in epithelial ovarian cancer. Int J Biol Macromol 85: 405-416, 2016.
35. Zhang LH, Yin AA, Cheng JX, Huang HY, Li XM, Zhang YQ, Han N and Zhang X: TRIM24 promotes glioma progression and enhances chemoresistance through activation of the PI3K/Akt signaling pathway. Oncogene 34: 600-610, 2015.
36. Xue D, Zhang X, Zhang X, Liu J, Li N, Liu C, Liu Y and Wang P: Clinical significance and biological roles of TRIM24 in human bladder carcinoma. Tumour Biol 36: 6849-6855, 2015.
37. Miao ZF, Wang ZN, Zhao TT, Xu YY, Wu JH, Liu XY, Xu H, You Y and Xu HM: TRIM24 is upregulated in human gastric cancer and promotes gastric cancer cell growth and chemoresistance. Virchows Arch 466: 525-532, 2015.
38. Fang Z, Deng J, Zhang L, Xiang X, Yu F, Chen J, Feng M and Xiong J: TRIM24 promotes the aggression of gastric cancer via the Wnt/β-catenin signaling pathway. Oncol Lett 13: 1797-1806, 2017.
39. Jiang S, Minter LC, Stratton SA, Yang P, Abbas HA, Akdemir ZC, Pant V, Post S, Gagea M, Lee RG, et al: TRIM24 suppresses development of spontaneous hepatic lipid accumulation and hepatocellular carcinoma in mice. J Hepatol 62: 371-379, 2015.
40. Bazar L, Harris V, Sunitha I, Hartmann D and Avigan M: A transactivator of c-myc is coordinately regulated with the proto-oncogene during cellular growth. Oncogene 10: 2229-2238, 1995.
41. Zhang J and Chen QM: Far upstream element binding protein 1: A commander of transcription, translation and beyond. Oncogene 32: 2907-2916, 2013.
42. Kozma L, Kiss I, Nagy A, Szakáll S and Ember I: Investigation of c-myc and K-ras amplification in renal clear cell adenocarcinoma. Cancer Lett 111: 127-131, 1997.
43. Lian Y, Niu X, Cai H, Yang X, Ma H, Ma S, Zhang Y and Chen Y: Clinicopathological significance of c-MYC in esophageal squamous cell carcinoma. Tumour Biol 39: 1-7, 2017.
44. Rabenhorst U, Beinoraviciute-Kellner R, Brezniceanu ML, Joos S, Devens F, Lichter P, Rieker RJ, Trojan J, Chung HJ, Levens DL and Zörnig M: Overexpression of the far upstream element binding protein 1 in hepatocellular carcinoma is required for tumor growth. Hepatology 50: 1121-1129, 2009.
45. Malz M, Weber A, Singer S, Riehmer V, Bissinger M, Riener MO, Longerich T, Soll C, Vogel A, Angel P, et al: Overexpression of far upstream element binding proteins: A mechanism regulating proliferation and migration in liver cancer cells. Hepatology 50: 1130-1139, 2009.
46. Yang L, Zhu JY, Zhang JG, Bao BJ, Guan CQ, Yang XJ, Liu YH, Huang YJ, Ni RZ and Ji LL: Far upstream element-binding protein 1 (FUBP1) is a potential c-Myc regulator in esophageal squamous cell carcinoma (ESCC) and its expression promotes ESCC progression. Tumour Biol 37: 4115-4126, 2016.
47. Khageh Hosseini S, Kolterer S, Steiner M, von Manstein V, Gerlach K, Trojan J, Waidmann O, Zeuzem S, Schulze JO, Hahn S, et al: Camptothecin and its analog SN-38, the active metabolite of irinotecan, inhibit binding of the transcriptional regulator and oncoprotein FUBP1 to its DNA target sequence FUSE. Biochem Pharmacol 146: 53-62, 2017.
48. Venturutti L, Cordo Russo RI, Rivas MA, Mercogliano MF, Izzo F, Oakley RH, Pereyra MG, De Martino M, Proietti CJ, Yankilevich P, et al: MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1. Oncogene 35: 6189-6202, 2016.
49. Disteldorf EM, Krebs CF, Paust HJ, Turner JE, Nouailles G, Tittel A, Meyer-Schwesinger C, Stege G, Brix S, Velden J, et al: CXCL5 drives neutrophil recruitment in TH17-mediated GN. J Am Soc Nephrol 26: 55-66, 2015.

50. Mei J, Liu Y, Dai N, Hoffmann C, Hudock KM, Zhang P, Guttentag SH, Kolls JK, Oliver PM, Bushman FD and Worthen GS: Cxcr2 and Cxcl5 regulate the IL-17/G-CSF axis and neutrophil homeostasis in mice. J Clin Invest 122: 974-986, 2012.
51. Nouailles G, Dorhoi A, Koch M, Zerrahn J, Weiner J III, Faé KC, Arrey F, Kuhlmann S, Bandermann S, Loewe D, *et al*: CXCL5-secreting pulmonary epithelial cells drive destructive neutrophilic inflammation in tuberculosis. J Clin Invest 124: 1268-1282, 2014.
52. Zhou SL, Dai Z, Zhou ZJ, Wang XY, Yang GH, Wang Z, Huang XW, Fan J and Zhou J: Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma. Hepatology 56: 2242-2254, 2012.
53. Speetjens FM, Kuppen PJ, Sandel MH, Menon AG, Burg D, van de Velde CJ, Tollenaar RA, de Bont HJ and Nagelkerke JF: Disrupted expression of CXCL5 in colorectal cancer is associated with rapid tumor formation in rats and poor prognosis in patients. Clin Cancer Res 14: 2276-2284, 2008.
54. Zheng J, Zhu X and Zhang J: CXCL5 knockdown expression inhibits human bladder cancer T24 cells proliferation and migration. Biochem Biophys Res Commun 446: 18-24, 2014.
55. Zhao J, Ou B, Han D, Wang P, Zong Y, Zhu C, Liu D, Zheng M, Sun J, Feng H and Lu A: Tumor-derived CXCL5 promotes human colorectal cancer metastasis through activation of the ERK/Elk-1/Snail and AKT/GSK3β/β-catenin pathways. Mol Cancer 16: 70, 2017.
56. Zhou SL, Zhou ZJ, Hu ZQ, Li X, Huang XW, Wang Z, Fan J, Dai Z and Zhou J: CXCR2/CXCL5 axis contributes to epithelial-mesenchymal transition of HCC cells through activating PI3K/Akt/GSK-3β/Snail signaling. Cancer Lett 358: 124-135, 2015.
57. Huang P, Xu X, Wang L, Zhu B, Wang X and Xia J: The role of EGF-EGFR signalling pathway in hepatocellular carcinoma inflammatory microenvironment. J Cell Mol Med 18: 218-230, 2014.
58. Johnson KM, Phan TTN, Albertolle ME and Guengerich FP: Human mitochondrial cytochrome P450 27C1 is localized in skin and preferentially desaturates trans-retinol to 3,4-dehydroretinol. J Biol Chem 292: 13672-13687, 2017.
59. Enright JM, Toomey MB, Sato SY, Temple SE, Allen JR, Fujiwara R, Kramlinger VM, Nagy LD, Johnson KM, Xiao Y, *et al*: Cyp27c1 red-shifts the spectral sensitivity of photoreceptors by converting vitamin A1 into A2. Curr Biol 25: 3048-3057, 2015.
60. Morshedian A, Toomey MB, Pollock GE, Frederiksen R, Enright JM, McCormick SD, Cornwall MC, Fain GL and Corbo JC: Cambrian origin of the CYP27C1-mediated vitamin A_1-to-A_2 switch, a key mechanism of vertebrate sensory plasticity. R Soc Open Sci 4: 170362, 2017.
61. Edge SB and Compton CC: The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17: 1471-1474, 2010.